According to new research announced today, the fragile X syndrome (FXS) market across the USA and Germany is projected to ...

Stoke Therapeutics’ stock climbed 8% early Tuesday, after the company and Biogen today announced a collaboration to develop ...

Nura Bio, a US biopharma developing neuroprotective, small molecule therapies for the treatment of debilitating neurological ...

Swiss dermatology company Galderma has announced two European approvals for Nemluvio (nemolizumab) to treat both atopic ...

California-based Arcus Biosciences, a biopharma developing differentiated molecules and combination therapies for people with ...

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Altuvoct (efanesoctocog alfa) to be used to ...

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application ...

Israel-based clinical-stage company Purple Biotech today announced it is advancing into a Phase II study with NT219 in ...

Germany’s Formycon has decided today to prematurely terminate the Phase III trial (Lotus) for its biosimilar candidate FYB206 ...

Germany’s Merck KGaA has appointed three new members to its executive board, which it says is a natural evolution in the company’s leadership as it continues to implement its growth strategy.

Epitopea, an Anglo-Canadian company developing accessible, off-the-shelf RNA-based immunotherapies for cancer, has announced a license and research collaboration deal with US pharma giant Merck & Co ...

US pharma giant Merck & Co today announced that the European Commission (EC) has conditionally approved two indications for Welireg (belzutifan), its oral hypoxia-inducible factor-2 alpha (HIF-2α) ...